OpenEvidence, an AI app co-founded by Daniel Nadler in 2022, is a clinician-focused platform used by over a million U.S. healthcare professionals to access up-to-date medical information and aid treatment decisions.

Founder Nadler frames the mission in terms of impact, citing improved access for rural physicians to subspecialists and broader equity in care, while stressing that the platform cannot replace clinicians.

OpenEvidence competes with health offerings from firms like OpenAI and Anthropic, but currently holds a head start in clinician adoption.

Growth has come from word-of-mouth and direct physician sign-ups, with the platform training on top scientific journals to deliver rapid, validated answers while complying with patient information laws.

OpenEvidence previously partnered with the clinician network Better Evidence during the Ebola crisis to support frontline use.

In July 2026 alone, clinicians consulted OpenEvidence 38 million times, with the company projecting that more than 300 million Americans will be treated by a doctor using OpenEvidence this year.

Individual doctors, including Sudheesha Perera of Yale, have adopted OpenEvidence for its speed and current-research edge, helping to drive broader institutional buy-in from major hospitals like Mount Sinai and Mayo Clinic along with medical societies.

The startup closed a $250 million funding round early this year, led by Thrive Capital and DST, valuing the company at about $12 billion.

Despite momentum, Nadler acknowledges lingering skepticism toward health-tech tools and the risk that even well-funded tools can go underutilized in hospital systems.

OpenEvidence reported more than $100 million in annualized revenue last year, largely from advertising to pharmaceutical companies, with the goal of keeping the platform free for users.